{"transactions":[{"id":740193,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":38838,"kind":"person","name":"Parsons Erin","position":1,"cik":"0001895795","reported_name":"Parsons Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T16:15:52.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027."}],"balance_after":25000,"derivative":{"exercise_price":2.63,"exercise_date":"2027-06-10","expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001895795-26-000001","document":"wk-form4_1781295350.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895795/000189579526000001/wk-form4_1781295350.xml","form_type":"4"}},{"id":1183898,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":38838,"kind":"person","name":"Parsons Erin","position":1,"cik":"0001895795","reported_name":"Parsons Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T20:15:58.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on April 1, 2026."}],"balance_after":20000,"derivative":{"exercise_price":2.93,"exercise_date":"2026-04-01","expiration_date":"2035-04-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001372514-25-000029","document":"wk-form4_1743639351.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895795/000137251425000029/wk-form4_1743639351.xml","form_type":"4"}},{"id":1403815,"issuer":{"id":11664,"kind":"organization","name":"ALIMERA SCIENCES INC","symbol":"ALIM"},"owners":[{"id":38838,"kind":"person","name":"Parsons Erin","position":1,"cik":"0001895795","reported_name":"Parsons Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-18T21:52:44.000Z","date":"2024-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3255,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the \"Merger Agreement\"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation (\"Parent\") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the \"Effective Time\"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an \"Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the \"Closing Cash Consideration\") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to:"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right (\"CVR\") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the \"Merger Agreement\"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation (\"Parent\") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the \"Effective Time\"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an \"Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the \"Closing Cash Consideration\") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right (\"CVR\") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent."}],"balance_after":0,"derivative":{"exercise_price":5.23,"expiration_date":"2031-11-29","underlying":"Common Stock","underlying_shares":3255},"source":{"system":"sec-edgar","filing":"0001104659-24-101108","document":"tm2424353-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1895795/000110465924101108/tm2424353-7_4seq1.xml","form_type":"4"}},{"id":1403814,"issuer":{"id":11664,"kind":"organization","name":"ALIMERA SCIENCES INC","symbol":"ALIM"},"owners":[{"id":38838,"kind":"person","name":"Parsons Erin","position":1,"cik":"0001895795","reported_name":"Parsons Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-18T21:52:44.000Z","date":"2024-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the \"Merger Agreement\"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation (\"Parent\") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the \"Effective Time\"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an \"Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the \"Closing Cash Consideration\") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to:"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right (\"CVR\") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the \"Merger Agreement\"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation (\"Parent\") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the \"Effective Time\"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an \"Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the \"Closing Cash Consideration\") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right (\"CVR\") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent."}],"balance_after":0,"derivative":{"exercise_price":2.7183,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001104659-24-101108","document":"tm2424353-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1895795/000110465924101108/tm2424353-7_4seq1.xml","form_type":"4"}},{"id":1403813,"issuer":{"id":11664,"kind":"organization","name":"ALIMERA SCIENCES INC","symbol":"ALIM"},"owners":[{"id":38838,"kind":"person","name":"Parsons Erin","position":1,"cik":"0001895795","reported_name":"Parsons Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-18T21:52:44.000Z","date":"2024-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the \"Merger Agreement\"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation (\"Parent\") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the \"Effective Time\"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an \"Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the \"Closing Cash Consideration\") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to:"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right (\"CVR\") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the \"Merger Agreement\"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation (\"Parent\") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the \"Effective Time\"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an \"Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the \"Closing Cash Consideration\") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right (\"CVR\") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent."}],"balance_after":0,"derivative":{"exercise_price":2.99,"expiration_date":"2033-10-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-24-101108","document":"tm2424353-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895795/000110465924101108/tm2424353-7_4seq1.xml","form_type":"4"}},{"id":1460437,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":38838,"kind":"person","name":"Parsons Erin","position":1,"cik":"0001895795","reported_name":"Parsons Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-03T15:15:58.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":1778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on July 1, 2025."}],"balance_after":1778,"derivative":{"exercise_price":4.35,"exercise_date":"2025-07-01","expiration_date":"2034-07-01","underlying":"Common Stock","underlying_shares":1778},"source":{"system":"sec-edgar","filing":"0001372514-24-000092","document":"wk-form4_1720034152.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895795/000137251424000092/wk-form4_1720034152.xml","form_type":"4"}},{"id":1480948,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":38838,"kind":"person","name":"Parsons Erin","position":1,"cik":"0001895795","reported_name":"Parsons Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-13T15:51:05.000Z","date":"2024-06-13","kind":"purchase","planned":false,"acquired":true,"shares":5260,"price":4.88,"value":25668.8,"ownership":{"direct":false,"nature":"By spouse"},"balance_after":5260,"source":{"system":"sec-edgar","filing":"0001372514-24-000061","document":"wk-form4_1718308256.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895795/000137251424000061/wk-form4_1718308256.xml","form_type":"4"}},{"id":1765559,"issuer":{"id":11664,"kind":"organization","name":"ALIMERA SCIENCES INC","symbol":"ALIM"},"owners":[{"id":38838,"kind":"person","name":"Parsons Erin","position":1,"cik":"0001895795","reported_name":"Parsons Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-04T16:46:24.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in equal monthly installments beginning on August 1, 2023. Vests in full on the earlier of August 1, 2024 or the date of the Issuer's 2024 annual meeting of stockholders, provided the Reporting Person provides continuous service to the Issuer through such date, with the final installment adjusted as necessary to avoid any fractional shares in any installment."}],"balance_after":50000,"derivative":{"exercise_price":2.99,"expiration_date":"2033-10-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-23-051941","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895795/000095017023051941/ownership.xml","form_type":"4"}},{"id":1767984,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":38838,"kind":"person","name":"Parsons Erin","position":1,"cik":"0001895795","reported_name":"Parsons Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-10-03T16:43:22.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on September 29, 2024."}],"balance_after":5000,"derivative":{"exercise_price":0.5677,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001372514-23-000142","document":"wk-form4_1696365787.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895795/000137251423000142/wk-form4_1696365787.xml","form_type":"4"}},{"id":1966410,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":38838,"kind":"person","name":"Parsons Erin","position":1,"cik":"0001895795","reported_name":"Parsons Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-07T20:15:42.000Z","date":"2023-03-03","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on March 3, 2024."}],"balance_after":8000,"derivative":{"exercise_price":3.83,"expiration_date":"2033-03-03","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001372514-23-000037","document":"wf-form4_167823812887709.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895795/000137251423000037/wf-form4_167823812887709.xml","form_type":"4"}},{"id":2060724,"issuer":{"id":11664,"kind":"organization","name":"ALIMERA SCIENCES INC","symbol":"ALIM"},"owners":[{"id":38838,"kind":"person","name":"Parsons Erin","position":1,"cik":"0001895795","reported_name":"Parsons Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-06T19:26:55.000Z","date":"2023-01-04","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in full on the date of the Issuer's annual meeting of stockholders in 2023 or any special meeting held in lieu thereof, provided the Reporting Person provides continuous service to the Issuer through such date."}],"balance_after":6000,"derivative":{"exercise_price":2.7183,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001474506-23-000013","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895795/000147450623000013/primary_doc.xml","form_type":"4"}},{"id":2414432,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":38838,"kind":"person","name":"Parsons Erin","position":1,"cik":"0001895795","reported_name":"Parsons Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-03T19:04:06.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2023."}],"balance_after":5000,"derivative":{"exercise_price":0.77,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-22-011494","document":"tm225348d6_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1895795/000110465922011494/tm225348d6_4.xml","form_type":"4"}},{"id":2414431,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":38838,"kind":"person","name":"Parsons Erin","position":1,"cik":"0001895795","reported_name":"Parsons Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-03T19:04:06.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan in connection with the Reporting Person's appointment to the Issuer's Board of Directors. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years."}],"balance_after":4000,"derivative":{"exercise_price":0.77,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001104659-22-011494","document":"tm225348d6_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895795/000110465922011494/tm225348d6_4.xml","form_type":"4"}},{"id":2489114,"issuer":{"id":11664,"kind":"organization","name":"ALIMERA SCIENCES INC","symbol":"ALIM"},"owners":[{"id":38838,"kind":"person","name":"Parsons Erin","position":1,"cik":"0001895795","reported_name":"Parsons Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-02T13:17:15.000Z","date":"2021-11-30","kind":"grant","acquired":true,"shares":3255,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Becomes exercisable in equal monthly installments of 465 shares on the 15th day of each month from December 15, 2021 through June 15, 2022, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date."}],"balance_after":3255,"derivative":{"exercise_price":5.23,"expiration_date":"2031-11-29","underlying":"Common Stock","underlying_shares":3255},"source":{"system":"sec-edgar","filing":"0001474506-21-000171","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895795/000147450621000171/primary_doc.xml","form_type":"4"}}]}